# Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

> **NCT00376584** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 825 (actual)

## Conditions studied

- Hypercholesteremia
- Hyperlipidemia

## Interventions

- **DRUG:** MK-0524A
- **DRUG:** ER Niacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00376584
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 825 (ACTUAL)
- **Last updated:** 2017-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376584, "Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00376584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*